Abstract
A new real-time polymerase chain reaction (PCR) method was developed for quantitation of Enterocytozoon bieneusi DNA in sequential stool specimens from immunocompromised patients with intestinal microsporidiosis. Patients were treated with fumagillin (n = 6) or with placebo (n = 6), in a randomized comparative trial. At baseline, mean E. bieneusi DNA levels were not significantly different in stool specimens from the placebo group, compared with those from the fumagillin group (5.9 ± 0.4 vs. 5.9 ± 0.6 log10 copies/μL of stool suspension, respectively; P = .96). In the placebo group, parasitic burden remained stable during follow-up (P = .46), whereas, in the fumagillin group, E. bieneusi DNA levels dropped below the lower limit of detection in all patients (mean reduction from baseline, -4.7 log10 copies; P < .0001). Real-time PCR performed better than did semiquantitative assessments by microscopy, to measure parasitic burden. In conclusion, this real-time PCR assay is a reliable tool for quantitation of E. bieneusi DNA in stool specimens and for the monitoring of treatment efficacy.
Cite
CITATION STYLE
Menotti, J., Cassinat, B., Porcher, R., Sarfati, C., Derouin, F., & Molina, J. M. (2003). Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis. Journal of Infectious Diseases, 187(9), 1469–1474. https://doi.org/10.1086/374620
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.